
Vocera is a clinical communication and workflow platform owned by Stryker Corporation (NYSE: SYK). Founded in 2000 in San Jose, California, Vocera provides wearable hands-free communication badges and software used by nurses and hospital staff. Stryker acquired Vocera in 2022 for $2.97 billion.
Parent Company
Acquired
2022
Status
Publicly Traded
Headquarters
| Brand | Parent Company | Ownership Type |
|---|---|---|
| Vocera | Stryker Corporation | Subsidiary |
Robert Shostak and Brent Lang founded Vocera Communications in 2000 in San Jose, California, to solve a hospital communication problem: nurses spent excessive time tracking down colleagues and information. Their solution was a wearable, voice-controlled hands-free badge enabling instant communication without phone or pager.
The Vocera Badge launched in 2002 and found adoption in hospitals where mobility and hands-free operation were critical. The product expanded into a communication platform connecting voice, text, and alert systems across hospital staff.
Vocera went public on NASDAQ in 2012. Through the following decade, it evolved from a device company into a clinical communications platform: the Vocera platform unified nurse call, alarm notification, messaging, and workflow management across hospitals. Acquisitions including Extension Healthcare (2016) and EASE Applications (2020) expanded into alarm management and patient-family communication.
Stryker announced the Vocera acquisition in January 2022 for $79.25 per share, approximately $2.97 billion, closing in February 2022. The deal gave Stryker the leading clinical communications platform and a digital health software business complementary to its physical medical devices.
Under Stryker, Vocera continues to operate under its brand name, integrating with Stryker's Medical division's broader hospital technology stack including beds, equipment, and Sage patient-care products.
Is Stryker publicly traded?
Yes. Stryker Corporation trades on the New York Stock Exchange under the ticker SYK and is an S&P 500 component.
When was Stryker founded?
Dr. Homer Stryker founded the Orthopaedic Frame Company in 1941 in Kalamazoo, Michigan. It was renamed Stryker Corporation in 1964 and went public in 1979.
Who owns Stryker?
Stryker is a public company with institutional investors holding most shares. Kevin Lobo has served as CEO since 2012.
What brands does Stryker own?
Stryker's key brands include the Stryker masterbrand, Mako SmartRobotics (surgical robots), Sage Products (patient care), and Vocera (clinical communications). Its 2025 acquisition of Inari Medical added venous thromboembolism devices.
What is Stryker's revenue?
Stryker reported net sales of $25.1 billion for fiscal year 2025, up 11.2%, with net earnings of $3.2 billion and adjusted EPS of $13.63.
Vocera operates under Stryker Corporation's sustainability and data security programs. As a healthcare communications platform, it is subject to HIPAA compliance and maintains HITRUST and security certifications for its software.
The brand holds no independent environmental certification. Its software's role in improving clinical workflow efficiency is its primary social impact contribution.
No direct competitors found in the same category. This could be because Voceraoperates in a unique market segment or we're still building our competitor database.
Looking for brands with different ownership structures? These similar brands are not owned by Stryker Corporation, giving you alternative choices that support different corporate structures.
Healthcare PharmaceuticalsOwned by Amgen Inc.
Master biotechnology brand of Amgen Inc., the world's largest independent biotech, covering its full portfolio of biologic medicines.
Amgen operates independently without a large parent corporation.
Healthcare PharmaceuticalsOwned by Novo Nordisk
Danish pharmaceutical company specializing in diabetes care and obesity treatment. Founded in 1923, headquartered in Bagsvaerd, Denmark. World leader in diabetes care and a leader in obesity treatment with Ozempic, Wegovy, and the investigational CagriSema. CEO Lars Fruergaard Jorgensen departed in March 2025; interim leadership under board chairman Helge Lund until a permanent CEO is appointed.
Novo Nordisk operates independently without a large parent corporation.
Healthcare PharmaceuticalsOwned by Alcon Inc.
Independent publicly traded global eye care company headquartered in Geneva, Switzerland, specializing in surgical equipment, contact lenses, and ophthalmic products. Spun off from Novartis in April 2019.
Alcon operates independently without a large parent corporation.
Healthcare PharmaceuticalsOwned by Walgreens Boots Alliance
Boots is the UK's leading pharmacy-led health and beauty retailer, founded in 1849, now operating as The Boots Group under Sycamore Partners since August 2025.
Boots is privately owned, unlike Vocera which is under a publicly traded parent company.
Healthcare PharmaceuticalsOwned by Walgreens Boots Alliance
Duane Reade is a New York City drugstore chain owned by Walgreen Co. under Sycamore Partners, operating approximately 90 stores across the five boroughs.
Duane Reade is privately owned, unlike Vocera which is under a publicly traded parent company.
Healthcare PharmaceuticalsOwned by GE HealthCare Technologies Inc.
Independent publicly traded healthcare technology company spun off from General Electric in January 2023, providing medical imaging, diagnostics, and healthcare IT solutions globally.
GE HealthCare operates independently without a large parent corporation.
Discover popular brands and companies in the Healthcare & Pharmaceuticals category and related searches from other users.

Abbokinase (urokinase) is a thrombolytic medication historically used for pulmonary embolism and catheter clearance. Originally marketed by Abbott Laboratories, now owned by Microbix Biosystems as Kinlytic. FDA-approved since 1978.

Pfizer's respiratory syncytial virus (RSV) vaccine approved for older adults, maternal immunization to protect infants, and younger at-risk adults. Launched 2023.

Prescription isotretinoin brand developed by Roche and approved by the FDA in 1982 for severe nodular acne. Roche discontinued the brand name in the United States in 2009; the drug continues as Roaccutane in international markets.